Results 181 to 190 of about 21,159,025 (295)

From anthelmintic to neuro‐oncology: A systematic review of mebendazole repurposing for brain tumour therapy

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aim Mebendazole (MBZ), a benzimidazole anthelmintic with established clinical use, has emerged as a repurposing candidate for primary brain tumours due to its multimodal anticancer actions and central nervous system penetrance. This systematic review synthesizes preclinical and clinical evidence evaluating MBZ's efficacy, mechanisms of action ...
Ciara B. Blum, Milli McMenamin, Tessa Khoo, John M. Edwin, Prathibha Jose, Liam A. O’Callaghan   +5 more
wiley   +1 more source

Safety and efficacy of port use for CAR T-cell infusion in large B-cell lymphoma. [PDF]

Blood Cancer J
Hunzeker ZE, Lionel A, Sun X, Feng L, Ahmed S, Ayers A, de Castro M, Varghese J, Ow K, Cain T, Santiago M, Nair S, Ramdial J, Shpall EJ, Neelapu SS, Strati P.   +15 more
europepmc   +1 more source

Regulatory harmonization: Evolution, globalization and future directions

British Journal of Clinical Pharmacology, EarlyView.
Regulatory harmonization has become an increasingly important and accepted approach to streamline regulatory review processes and expedite access to safe, effective and high‐quality medicines globally. This review explores the evolution and current status of regulatory harmonization, convergence and reliance initiatives.
Orin Chisholm, Elaine Y. L. Blair, Christine Y. Lu   +2 more
wiley   +1 more source

High-grade B-cell lymphoma presenting with bulbar palsy and Tapia syndrome: A case report. [PDF]

Medicine (Baltimore)
Luo H, Zhao Z, Liu B.
europepmc   +1 more source

B cell lymphoma

, 2016
B cell lymphoma is the most common hematologic malignancy. Besides alterations in the malignant lymphoma cells, also the interaction with the microenvironment has gained much interest in recent years. The aim of this thesis is to characterize the malignant cells as well as the surrounding microenvironment by proteomics and by flow analysis.In the first
openaire   +1 more source

Model‐informed optimal dose selection of golcadomide in combination with R‐CHOP in patients with previously untreated aggressive B‐cell lymphoma

British Journal of Clinical Pharmacology, EarlyView.
Aims Golcadomide is a potential first‐in‐class oral CELMoD™ agent for the treatment of lymphoma. This study aims to develop model‐informed drug development (MIDD) approaches to support optimal dose selection of golcadomide in combination with immunotherapy rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R‐CHOP) in alignment with ...
Xirong Zheng, Zhiling Yu, Mark Kaplan, Argyrios Gkasiamis, Akshay Sudhindra, Li Zhu, Manisha Lamba, Fan Wu   +7 more
wiley   +1 more source

B-Cell Lymphomas

, 2020
Subramanian Kalaivani Selvi, B.H. Srinivas, Sadhanandham Shrinuvasan   +2 more
openaire   +3 more sources

Hodgkin Reed-Sternberg-Like Cells in T-Cell/Histiocyte-Rich Large B-Cell Lymphoma. [PDF]

EJHaem
Mustaki U, Lade S, Anderson MA, Chan KL.
europepmc   +1 more source

Cell and Gene Therapies Manufacturing Challenges and Integrated Good Manufacturing Practices Solutions: A Lifecycle Perspective

Biotechnology and Bioengineering, EarlyView.
Lifecycle perspective on cell and gene therapy manufacturing challenges and enabling GMP solutions. ABSTRACT Cell and gene therapies (CGTs) are revolutionizing modern medicine; however, making these advanced medicines scalable and readily available to commercial manufacturers worldwide is a major challenge. The number of approved CGT products continues
Rajath Samaga, Udisha Singh, Sachin Dattram Pawar   +2 more
wiley   +1 more source

Nanoagonist‐mediated spatiotemporal reprogramming of macrophage phenotypes to potentiate tumor immunotherapy

BMEMat, EarlyView.
This review systematically summarizes the major molecular mechanisms governing TAM polarization and their coordinated interactions. It further highlights recent advances in nanoagonist‐based strategies that intervene in these pathways to reprogram TAMs, critically discussing their therapeutic potential, current limitations, and translational prospects.
Siqi Fang, Fengfeng Xiao, Ruie Chen, Cuixia Lu, Yi Ju, Mingqing Yuan, Yunlu Dai, Liewei Wen   +7 more
wiley   +1 more source